Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 8Myeloid 5Other solid neoplasm 2Lymphoid 2Tumor-Agnostic 1Plasma cell 1Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Rituximab 376Cyclophosphamide 179Bendamustine Hydrochloride 109obinutuzumab 100Vincristine 94fludarabine 92ibrutinib 89Prednisone 89Doxorubicin 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24tositumomab I-131 22Prednisolone 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × pevonedistat × Lymphoid × Clear all
NCT00911066 2013-12-05

MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
72 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00722488 2013-11-18

Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
56 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡